Susan M. O'Brien

Associate Director for Clinical Science, Chao Family Comprehensive Cancer Center

Medical Director, Sue & Ralph Stern Center for Clinical Trials & Research

Professor, Division of Hematology/Oncology
School of Medicine

M.D., University of Medicine & Dentistry of New Jersey Medical School, NJ


B.A., Mt. Holyoke College, South Hadley, MA, Biochemistry

Phone: (714) 456-7511
Fax: (714) 456-6025
Email: obrien@uci.edu

University of California, Irvine
101 The City Drive South
Building 56, Room 232
Mail Code: 2675
Orange, CA 92868

picture of Susan M. O'Brien

Research
Interests
Hematologic malignancies, both acute and chronic leukemia
   
URL Chao Family Comprehensive Cancer Center
   
Publications Selected Peer-Reviewed Journal Articles:

Thomas DA, O'Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, Ravandi F, Verstovsek S, Jorgensen JL, Bueso-Ramos C, Andreeff M, Pierce S, Garris R, Keating MJ, Cortes J, Kantarjian HM. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chronosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol 2010 Aug 20;28(24):3880-9. Epub 2010 Jul 26.

Mattiuzzi GN, Cortes JE, Blamble DA, Bekele BN, Xiao L, Cabanillas M, Borthakur G, O'Brien S, Kantarjian H. Daily palonosetron is superior to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia. Cancer 2010 Dec 15;116(24):5659-66.

O'Brien S, Berman E, Moore JO, Pinilla-Ibarz J, Radich JP, Shami PJ, Smith BD, Snyder DS, Sundar HM, Talpaz M, Wetzler M. NCCN task force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia. J Natl Compr Canc Netw 2011 Feb;9 Suppl 2:S1-S25.

Strati P, Wierda W, Burger J, Ferrajoli A, Tam C, Lerner S, Keating MJ, O'Brien S. Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: analysis of persistent and new-onset cytopenia. Cancer 2013 Nov 1;119(21):3805-11. Epub 2013 Aug 13.

O'Brien S, Furman RR, Coutre SE, Sharman JP, Burger JA, Blum KA, Grant B, Richards DA, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Izumi R, Hamdy A, Chang BY, Graef T, Clow F, Buggy JJ, James DF, Byrd JC. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncol 2014 Jan;15(1):48-58. Epub 2013 Dec 10.

Faderl S, Balakrishnan K, Thomas DA, Ravandi F, Borthakur G, Burger J, Ferrajoli A, Cortes J, O'Brien S, Kadia T, Feliu J, Plunkett W, Gandhi V, Kantarjian HM. Phase I and extension study of clofarabine plus cyclophosphamide in patients with relapsed/refractory acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk 2014 Jun;14(3):231-8. Epub 2013 Dec 17.

Li P, Harris D, Liu Z, Rozovski U, Ferrajoli A, Wang Y, Bueso-Ramos C, Hazan-Halevy I, Grgurevic S, Wierda W, Burger J, O'Brien S, Faderl S, Keating M, Estrov Z. STAT3-Activated GM-CSFRalpha Translocates to the Nucleus and Protects CLL Cells from Apoptosis. Mol Cancer Res 2014 Sep;12(9):1267-82. Epub 2014 May 16.

Burger JA, Keating MJ, Wierda WG, Hartmann E, Hoellenriegel J, Rosin NY, de Weerdt I, Jeyakumar G, Ferrajoli A, Cardenas-Turanzas M, Lerner S, Jorgensen JL, Nogueras-Gonzalez GM, Zacharian G, Huang X, Kantarjian H, Garg N, Rosenwald A, O’Brien S. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm phase 2 study. Lancet Oncol 2014 Sep:15(10):1090-9.

Kantarjian H, O’Brien S, Jabbour E, Barnes G, Pathak A, Cortes J. Effectiveness of hemoharringtonine (omacetaxine mepesuccinate) for treatment of acute myeloid leukemia: a meta-analysis of Chinese studies. Clin Lymphoma Myeloma Leuk. 2015 Jan;15(1):13-21.

Byrd J, Furman R, Coutre S, Burger J, Blum K, Coleman M, Wierda W, Jones J, Zhao W, Heerema N, Johnson A, Shaw Y, Bilotti E, Zhou C, James D, O’Brien, S. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood 2015 Feb 19.

Daver N, Kantarjian H, Marcucci G, Pierce S, Brandt M, Dinardo C, Pemmaraju N, Garcia-Manero G, O’Brien S, Ferrajoli A, Verstovsek S, Popat U, Hosing C, Anderlini P, Borthakur G, Kadia T, Cortes J, Ravandi F. Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis. Br J Haematol. 2015 Mar;168(5):646-53. Epub 2014 Oct 14.

Brown JR, Barrientos JC, Barr PM, Flinn IW, Burger JA, Tran A, Clow F, James DF, Graef T, Friedberg JW, Rai K, O’Brien S. The Bruton’s tyrosine kinase (BTK) inhibitor, ibrutinib, with chemoimmunotherapy in patients with chronic lymphocytic leukemia. Blood Epub 2015 Mar 9
   
Professional
Societies
American Association for Cancer Research
American Society of Hematology
CLL Research Consortium
National Comprehensive Cancer Network, CML Guidelines Panel
Lymphoma Research Foundation Scientific Advisory Board
National Comprehensive Cancer Network, ALL Guidelines Panel
   
   
Link to this profile http://www.faculty.uci.edu/profile.cfm?faculty_id=6133
   
Last updated 04/24/2015